April 5, 2022
COVAIL Trial
Phase 2 Additional COVID-19 Vaccine Booster Trial The University of Washington is seeking volunteers for the COVID-19 VAriant Immunologic Landscape (COVAIL) Trial, a phase 2 additional COVID-19 vaccine booster trial. The purpose of this clinical trial is to test the safety and effectiveness of additional COVID-19 booster doses in people who have already received a…
January 5, 2022
NIAID Letter to Mix & Match Trial Participants
We now have early results from the participants who received their original COVID-19 vaccine regimen before they joined the study, then got a COVID-19 booster dose during the trial of either the Moderna vaccine (standard 100 mcg dose), the Janssen vaccine, or the Pfizer-BioNTech vaccine.
December 20, 2021
Novavax Letter to PREVENT-19 Trial Participants
We remain sincerely grateful for your participation in the PREVENT-19 clinical trial and your significant contribution to medical research addressing COVID-19. We are writing to provide an update on Novavax’ COVID-19 vaccine program. Foremost is the exciting news that the Novavax COVID-19 vaccine demonstrated high level efficacy in our PREVENT-19 Phase 3 trial in the U.S. and Mexico.
July 12, 2021
“Mix ‘n Match” Booster COVID-19 Vaccine Clinical Trial
The University of Washington is seeking volunteers for a Phase 1/2 COVID-19 vaccine booster trial to test the safety and effectiveness of additional doses of EUA vaccines in people who have received an EUA vaccine series.
April 21, 2021
Gritstone COVID-19 Vaccine Clinical Trial
Updated March 2022 The University of Washington Virology Research Clinic (VRC)/Vaccine & Treatment Evaluation Unit (VTEU) is conducting a clinical trial of a chimpanzee Adenovirus and self-amplifying mRNA prime-boost prophylactic vaccines against SARS-CoV-2 in healthy adults. The purpose of this trial is to test investigational booster vaccines for COVID-19. Participants who previously received a two-dose series…
December 28, 2020
Novavax COVID-19 Vaccine Trial
Update 2023: We are no longer enrolling for this study. We are enrolling members of the public in a clinical trial of a Phase 3 vaccine for the prevention of COVID-19. Our research site is testing the SARS-CoV-2 recombinant spike protein nanoparticle vaccine that is now being developed as part of Operation Warp Speed by a…